Trade Report: The Cooke & Bieler LP reached $39,709,000 position of Mednax Inc. (MD)

The Cooke & Bieler LP reached $39,709,000 position  of Mednax Inc. (MD)

Cooke & Bieler LP boosted its stake in shares of Mednax Inc. (NYSE:MD) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 548,235 shares of the company’s stock after buying an additional 6,910 shares during the period. Cooke & Bieler LP’s holdings in Mednax were worth $39,709,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Mednax by 4.1% in the first quarter. Geode Capital Management LLC now owns 572,404 shares of the company’s stock valued at $36,966,000 after buying an additional 22,537 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Mednax by 6.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,116,956 shares of the company’s stock worth $72,178,000 after buying an additional 66,098 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in Mednax by 7.9% in the first quarter. Pictet Asset Management Ltd. now owns 34,100 shares of the company’s stock worth $2,286,000 after buying an additional 2,500 shares during the last quarter. Lazard Asset Management LLC increased its stake in Mednax by 0.6% in the first quarter. Lazard Asset Management LLC now owns 167,229 shares of the company’s stock worth $10,806,000 after buying an additional 1,000 shares during the last quarter. Finally, State Street Corp increased its stake in Mednax by 3.8% in the first quarter. State Street Corp now owns 3,169,899 shares of the company’s stock worth $204,837,000 after buying an additional 116,369 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Mednax Inc. (NYSE:MD) traded up 0.14% on Monday, hitting $65.60. 312,094 shares of the stock were exchanged. The company has a market cap of $6.05 billion, a price-to-earnings ratio of 18.31 and a beta of 0.54. Mednax Inc. has a 52-week low of $61.40 and a 52-week high of $83.20. The company has a 50 day moving average of $65.79 and a 200 day moving average of $68.33.

Mednax (NYSE:MD) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.07 by $0.04. Mednax had a net margin of 11.17% and a return on equity of 14.88%. The company had revenue of $772 million for the quarter, compared to the consensus estimate of $775.68 million. During the same quarter in the prior year, the company earned $0.90 earnings per share. The company’s quarterly revenue was up 14.1% on a year-over-year basis. Equities research analysts forecast that Mednax Inc. will post $4.14 earnings per share for the current year.

MD has been the topic of a number of research analyst reports. Jefferies Group reduced their price target on shares of Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, August 26th. Mizuho restated a “buy” rating and issued a $79.00 price target on shares of Mednax in a research note on Tuesday, September 20th. Zacks Investment Research downgraded shares of Mednax from a “hold” rating to a “sell” rating in a research note on Wednesday, September 28th. JPMorgan Chase & Co. reduced their price target on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 29th. Finally, Citigroup Inc. reduced their price target on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. Mednax currently has an average rating of “Buy” and an average price target of $76.11.

In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the company’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the sale, the director now directly owns 12,755 shares in the company, valued at $829,202.55. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 2.40% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Related posts

Leave a Comment